Why? The next gv-971 may be born at the drug Fair

The invitation letter for the seminar on innovative drug development strategy of 2019 drug Fair will never be regretted in the world It will take another year to miss it At this time, when the new drug strategy starts, don't let Chunlai regret later News ①: good news for Alzheimer's patients! On November 2, the State Drug Administration approved the listing application of ganlute sodium capsule (gv-971, trade name "nine phase one"), a new drug for Alzheimer's disease, "for mild to moderate Alzheimer's disease, to improve patients' cognitive function" News ②: on July 5, the Chinese Academy of Medical Sciences issued a document stating that a class of innovative drug, colistin, jointly developed by it and Shenyang Tonglian Group Co., Ltd., was approved by the State Drug Administration for upper respiratory tract infection on June 24, 2019 News ③: on May 31, the State Food and Drug Administration approved the listing of carrizumab for injection, a programmed death receptor 1 (PD-1) inhibitor independently developed by Hengrui (trade name: Arica), which was approved for the treatment of relapsed or refractory classic Hodgkin's lymphoma patients undergoing at least second-line systemic chemotherapy News ④: on October 17, Weicai Co., Ltd announced that the National Drug Administration of China has approved the listing of weiketai, a new Weicai drug, which is suitable for the additional treatment of adults and children aged 12 and over with partial epilepsy (with or without secondary comprehensive epilepsy) News ⑤: on October 29, Pfizer updated its R & D pipeline catalog, showing seven newly "eliminated" research projects, mainly involving two major treatment fields of tumor and skin disease, including the bispecific antibody pf-06671008 developed in cooperation with macrogenomics The solid tumor drug was the first project based on macrogenomics dual specificity platform, but it was cut off by Pfizer only after entering clinical phase 1 Did you regret that you missed the last wave of innovative drugs? Can you still allow yourself to miss the new round of innovative medicine strategy seminar, which comprehensively guides the future strategic direction of innovative medicine? On December 4, the "2019 drug fair - innovative drug development strategy seminar" jointly held by Beijing xinkaiyuan Pharmaceutical Technology Co., Ltd., Chongqing Yaoyou Pharmaceutical Co., Ltd and yaozhi.com will be opened in Chongqing International Expo Center, focusing on the theme of "wisdom innovation and future" We sincerely invite domestic experts in the field of innovative drugs, pharmaceutical enterprises, industry media, etc to come together, adhere to the concept of cooperation and win-win, jointly discuss hot issues such as new drug research and development trends and key technologies, and jointly promote the healthy development of China's pharmaceutical industry At that time, we look forward to your visit! Best regards! 1、 Background with the gradual expansion of the global pharmaceutical market, the number and scale of Chinese pharmaceutical enterprises have increased, and innovative drugs have always been the Pearl of the pharmaceutical industry crown The national medical insurance catalogue increases the proportion of innovative drugs; the average time for mainstream innovative drugs to be listed in the medical insurance is reduced to less than one year; the proportion of domestic innovative drugs to be included in the medical insurance is increased to 100% In addition, with the continuous optimization of the domestic policy environment, the increasing capital injected into the pharmaceutical industry, and the return of a large number of high-tech talents, will vigorously promote the development of the domestic innovative drug market, and accelerate the innovation and R & D of domestic pharmaceutical enterprises in line with international standards In such an environment, how to deal with the opportunities and challenges brought by the new drug policy, how to realize the upgrading of innovative drug industry under the new drug policy, how to correctly evaluate the hot spots of new drug research and development oriented by clinical value, and how to draw lessons from the transfer and introduction of overseas rights and interests of innovative drugs will become the focus of attention in the field of domestic innovative drugs 2、 Forum overview conference name: Seminar on innovative drug development strategy conference time: December 4, 2019 (Wednesday) all day conference venue: room M202, hall N1, Chongqing International Expo Center (2nd floor of N1 corridor) sponsor: Beijing xinkaiyuan Pharmaceutical Technology Co., Ltd Co sponsor of Chongqing Yaoyou Pharmaceutical Co., Ltd.: yaozhi.com Conference scale: 200 people conference nature: free participation 3 Conference highlights 1 Pharmaceutical grand meeting, sharing several industry celebrities, gathering domestic innovative medicine elites, discussing cooperation and development plans, in-depth exchanges, and integrating industrial resources 2 Innovation driven, leading the navigation to gather the elites of pharmaceutical innovation drug, focusing on the research and development trend of innovative drugs at home and abroad, focusing on the analysis of relevant policies and market environment, guiding domestic innovative drug enterprises to avoid research and development risks, controlling future research and development points, and reducing research and development costs 3 Guided by medicine, the top pharmaceutical enterprises in the country gather in market value, and the business elites conspire for the disadvantages of the new market environment, throw out new ideas, and lead the new trend of the pharmaceutical market 4、 Agenda 5: brief introduction of speakers 1 Zhu Xizhen, deputy general manager of Beijing xinkaiyuan Pharmaceutical Technology Co., Ltd 2 Li Mei 3 Ge Zhimin, vice president of Yangpu Chenxing Pharmaceutical Co., Ltd and Deputy Secretary General of medical research and development and service branch of all China Federation of industry and Commerce 4 Guo Jianjun, general manager and head of organization of Hunan Hengxing Pharmaceutical Technology Co., Ltd 5 Liang Maozhi Deputy director of national drug clinical trial organization and director of phase I clinical trial Laboratory of West China Hospital, and visiting researcher of national safety evaluation center of traditional Chinese medicine of West China Hospital of Sichuan University 6 Meng Bayi Academy of Military Medical Sciences, master of pharmaceutical chemistry, master of computer science of New York City University, former intellectual property director, consultant and deputy general manager of Chongqing Huabang Pharmaceutical Co., Ltd He was a patent agent of China Patent Agency (Hong Kong) Co., Ltd 7 Yu Yongping, Zhuhai tus Boda Investment Management Co., Ltd 8 Chen Xiaoyong, chairman and senior engineer of Chongqing Dongde Pharmaceutical Technology Co., Ltd 9 Li Tianquan, senior engineer, co-founder and vice president of yaozhiwang 6 The meeting is free of charge The organizing committee will provide you with the relevant information of the conference, such as the journal and the information bag Please scan the QR code below or click "read the original" at the end of the article to register for the conference Special note: participants who register before November 30 and sign in in person can get a copy of "customized platform calendar of 2020 yaozhi.com" Registration link: https://c.eqxu.com/s/czenf49n scan the QR code below to sign up for the meeting contact 7 Support media Pharmaceutical intelligence media, Chinanet, interface news, Sina pharmaceutical, pharmaceutical guide, aoya.com, pharmaceutical circle, freehand brushwork, pharmaceutical research, biological exploration, Biovalley, pharmaceutical era, shell club, Huiyao coffee, Peiyou innovation, pharmaceutical research and development, pharmaceutical industry, a little information, meitong.com.. Editor in charge; penicillin